Sterling
AstraZeneca logo
AstraZeneca
Viking Therapeutics logo
Viking Therapeutics

Revenue Comparison

Chart: Revenue Comparison. Values in USD billions. In Q2 2026: AstraZeneca 15.384, Viking Therapeutics 0.

AstraZeneca vs Viking Therapeutics Net Worth and Market Cap

AstraZeneca (AZN) and Viking Therapeutics (VKTX) are peers in GLP-1. AstraZeneca reported revenue of $15.4B as of Q2 2026, compared with $0 for Viking Therapeutics. AstraZeneca leads on revenue.

Key differences

  • AstraZeneca's KPIs on Sterling include Alliance Revenue by Partnered Medicine (Quarterly) and AZD5004 + AZD6234 Trial Timeline: Oral GLP-1 + Oral Amylin.
  • Viking Therapeutics's KPIs on Sterling include Cash + Short-Term Investments (Quarterly) and Viking Oral VK2735 Phase 3 Timing.

Latest Quarter Comparison

Table: Latest Quarter Comparison. 15 rows across Metric, AstraZeneca, Viking Therapeutics.
MetricAstraZenecaViking Therapeutics
Market Cap--
Revenue$15.38B$0
Cost of Revenue$2.52B$0
Gross Profit$12.86B$0
Operating Income$3.16B$-164.00M
Net Income$2.51B$-158.00M
R&D Expense$4.05B$150.00M
Earnings Per Share$1.59-$1.37
Gross Margin83.6%-
Operating Margin20.6%-
Net Profit Margin16.3%-
Free Cash Flow$2.13B$-114.00M
Cumulative Free Cash Flow$121.22B$-747.00M
Operating Cash Flow$2.89B$-114.00M
Cash & Equivalents$4.89B$118.00M

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites